+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

, : Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Annals of Oncology 16(10): 1688-1694

BAY 43--9006, an oral multi-kinase inhibitor, targets serine-threonine kinases and receptor tyrosine kinases, and affects the tumor and vasculature in preclinical models. Based on its pharmacologic effect, it may be a useful cancer treatment. This study determined the maximum tolerated dose (MTD) of BAY 43-9006 in 42 patients with advanced, refractory metastatic or recurrent solid tumors. Dose-limiting toxicities (DLTs), safety, pharmacokinetics and tumor response were also evaluated. In this open-label, phase I, dose-escalation study, BAY 43--9,006 was administered orally in repeated cycles of 35 days (28 days on/7 days off). Eight doses were investigated: from 50 mg every fourth day to 600 mg twice daily. Treatment continued until unacceptable toxicity, tumor progression or death. The MTD was 400 mg twice daily. BAY 43-9006 was well tolerated, with mild to moderate toxicities; only six patients discontinued study therapy due to adverse events. DLTs consisted of hand-foot skin reaction in three of seven patients receiving 600 mg twice daily. Stable disease was achieved in 22% of patients; median duration of stable disease was 7.2 months. Consistent with its observed half-life of approximately 27 h, BAY 43-9, 006 accumulated on multiple dosing. Increases in exposure were less than proportional to the increases in dose. Results indicate that further clinical investigation of BAY 43--9006 is warranted, and suggest it could be a promising future therapy for patients with cancer.


PMID: 16006586

DOI: 10.1093/annonc/mdi310

Other references

Laux, W.; Sicher, W.; Blumenbach, D., 1979: Bibliographie der Pflanzenschutz-Literatur. See RAE/A 56, 2093.

Gil, A.; Roque, A.; Alemán, C., 2016: Meigs' syndrome. Medicina Clinica 145(2): 95-95

Burger W.C.; Din Z.Z.; Qureshi A.A., 1983: Suppression of cholesterogenesis in isolated hepatocytes by constituents of high protein barley flour. Federation Proceedings 42(7): ABSTRACT 1263

Boyd, E.M.; Kingsmill, C.J., 1951: The role of the liver in the detoxification of tetraethylthiuram disulphide (antabuse). American Journal of the Medical Sciences 221(4): 444-447

Autret-Leca, E.; Breteau, M., 2006: Homage to Professor Michel Breteau. Therapie 61(1): 87-88

Elbasha, E.H.; Chhatwal, J., 2015: Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers. Commonly used decision-analytic models for cost-effectiveness analysis simulate time in discrete steps. Use of discrete-time steps can introduce errors when calculating cumulative outcomes such as costs and quality-adjusted life-years. There are a...

Spencer, J.D.; Albutt, E.C., 1978: A simple method for measuring urinary meglumine ioglycamide concentrations. A new method for measuring the urinary concentration of meglumine ioglycamide, a radiological contrast agent, is described. The contrast is precipitated with acid, redissolved and estimated by UV spectrophotometry.

Baker, M.L.; Gemmell, R.T., 1999: Physiological changes in the brushtail possum following relocation from Armidale to Brisbane, Australia. To determine the effect of relocation on the health of possums the body weights and hormone and immune responses of six male and nine female brushtail possums were monitored for 20 weeks following transfer from the environs of Armidale into enclos...

Savir, Y.; Tu, B.P.; Springer, M., 2015: Competitive inhibition can linearize dose-response and generate a linear rectifier. Cell Systems 1(3): 238-245

Al-Aqeel, N.K.; Abdel-Mageed, E.M., 2011: Effects of hydroquinone on epidermal non-keratinocytes. International Journal of Health Sciences 5(2 Suppl 1): 9-11